Except for a PALB2 variant with conflicting evidence of pathogenicity (data not shown) investigated further, WES analysis using a virtual panel of 84 cancer-related genes did not reveal any actionable mutations in the 12 unresolved breast cancer patients. This evidence concerns the gene PALB2 and breast cancer.